21,249 Shares in AtriCure, Inc. (NASDAQ:ATRC) Acquired by Graham Capital Management L.P.

Graham Capital Management L.P. acquired a new position in shares of AtriCure, Inc. (NASDAQ:ATRC - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 21,249 shares of the medical device company's stock, valued at approximately $649,000.

A number of other large investors also recently added to or reduced their stakes in the business. Focus Partners Wealth bought a new stake in shares of AtriCure during the fourth quarter worth approximately $498,000. G2 Investment Partners Management LLC grew its holdings in AtriCure by 7.2% during the 4th quarter. G2 Investment Partners Management LLC now owns 29,691 shares of the medical device company's stock worth $907,000 after acquiring an additional 1,999 shares during the period. Centiva Capital LP acquired a new stake in AtriCure during the 4th quarter worth $510,000. BNP Paribas Financial Markets raised its position in shares of AtriCure by 676.4% during the 4th quarter. BNP Paribas Financial Markets now owns 97,310 shares of the medical device company's stock valued at $2,974,000 after acquiring an additional 84,776 shares during the last quarter. Finally, Ameriprise Financial Inc. acquired a new position in shares of AtriCure in the 4th quarter valued at $295,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.

AtriCure Stock Up 3.8%

ATRC stock traded up $1.25 during midday trading on Tuesday, hitting $33.65. The company's stock had a trading volume of 125,555 shares, compared to its average volume of 650,802. The company's fifty day moving average price is $32.40 and its 200 day moving average price is $34.86. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.65 and a quick ratio of 2.62. AtriCure, Inc. has a twelve month low of $18.94 and a twelve month high of $43.11. The stock has a market capitalization of $1.67 billion, a P/E ratio of -35.35 and a beta of 1.57.

AtriCure (NASDAQ:ATRC - Get Free Report) last released its earnings results on Tuesday, April 29th. The medical device company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.11. AtriCure had a negative return on equity of 6.80% and a negative net margin of 9.61%. The business had revenue of $123.62 million for the quarter, compared to the consensus estimate of $122.92 million. During the same quarter in the previous year, the business earned ($0.28) earnings per share. AtriCure's quarterly revenue was up 13.5% on a year-over-year basis. As a group, equities research analysts predict that AtriCure, Inc. will post -0.6 EPS for the current year.

Analysts Set New Price Targets

ATRC has been the subject of several research analyst reports. Oppenheimer boosted their price target on shares of AtriCure from $36.00 to $45.00 and gave the company an "outperform" rating in a report on Thursday, February 13th. Piper Sandler raised their price target on AtriCure from $40.00 to $50.00 and gave the stock an "overweight" rating in a research report on Thursday, February 13th. Stifel Nicolaus boosted their price objective on AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. cut their price target on shares of AtriCure from $51.00 to $46.00 and set an "overweight" rating on the stock in a research note on Thursday, March 27th. Finally, BTIG Research reissued a "buy" rating on shares of AtriCure in a research report on Thursday, March 27th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $50.67.

Insider Transactions at AtriCure

In other AtriCure news, Director Karen Prange sold 6,100 shares of the business's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total transaction of $232,532.00. Following the transaction, the director now owns 17,828 shares of the company's stock, valued at $679,603.36. The trade was a 25.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 3.50% of the company's stock.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.